Melvin Berger1. 1. Case Western Reserve University, Cleveland, OH, USA. melvin.berger@uhhospitals.org
Abstract
BACKGROUND: Flebogamma 5% dual inactivation and filtration (DIF) is the next generation of Flebogamma. Flebogamma was first licensed in 1992. The new preparation features additional viral inactivation and removal steps to enhance safety margins. OBJECTIVE: The purpose of this study was to evaluate the efficacy, safety, and pharmacokinetics of Flebogamma 5% DIF for immunoglobulin replacement therapy in primary immunodeficiency diseases (PID). METHODS: Flebogamma 5% DIF was administered at seven clinical sites to 46 subjects with well-defined primary immunodeficiency diseases at a dose of 300-600 mg/kg every 21-28 days for 12 months. RESULTS: The calculated serious bacterial infection rate was 0.021/subject/year. The incidence of adverse events considered potentially related to Flebogamma 5% DIF during or within 72 h after completing an infusion was approximately 10%. The half-life in serum of the administered IgG was around 31 days. CONCLUSIONS: Flebogamma 5% DIF is efficacious and safe, has adequate pharmacokinetic properties, is well-tolerated and maintains the profile of Flebogamma 5% for the treatment of primary humoral immunodeficiency diseases.
BACKGROUND:Flebogamma 5% dual inactivation and filtration (DIF) is the next generation of Flebogamma. Flebogamma was first licensed in 1992. The new preparation features additional viral inactivation and removal steps to enhance safety margins. OBJECTIVE: The purpose of this study was to evaluate the efficacy, safety, and pharmacokinetics of Flebogamma 5% DIF for immunoglobulin replacement therapy in primary immunodeficiency diseases (PID). METHODS:Flebogamma 5% DIF was administered at seven clinical sites to 46 subjects with well-defined primary immunodeficiency diseases at a dose of 300-600 mg/kg every 21-28 days for 12 months. RESULTS: The calculated serious bacterial infection rate was 0.021/subject/year. The incidence of adverse events considered potentially related to Flebogamma 5% DIF during or within 72 h after completing an infusion was approximately 10%. The half-life in serum of the administered IgG was around 31 days. CONCLUSIONS:Flebogamma 5% DIF is efficacious and safe, has adequate pharmacokinetic properties, is well-tolerated and maintains the profile of Flebogamma 5% for the treatment of primary humoral immunodeficiency diseases.
Authors: C Cunningham-Rundles; F P Siegal; E M Smithwick; A Lion-Boulé; S Cunningham-Rundles; J O'Malley; S Barandun; R A Good Journal: Ann Intern Med Date: 1984-10 Impact factor: 25.391
Authors: Mark Ballow; Paul J Pinciaro; Timothy Craig; Gary Kleiner; James Moy; Hans D Ochs; John Sleasman; William Smits Journal: J Clin Immunol Date: 2016-06-08 Impact factor: 8.317
Authors: Melvin Berger; Paul J Pinciaro; Arthur Althaus; Mark Ballow; Akhilesh Chouksey; James Moy; Hans Ochs; Mark Stein Journal: J Clin Immunol Date: 2009-12-08 Impact factor: 8.317
Authors: Richard L Wasserman; Joseph A Church; Mark Stein; James Moy; Martha White; Steven Strausbaugh; Harry Schroeder; Mark Ballow; James Harris; Isaac Melamed; David Elkayam; William Lumry; Daniel Suez; Syed M Rehman Journal: J Clin Immunol Date: 2012-03-06 Impact factor: 8.317
Authors: Elena E Perez; Jacques Hébert; Anne K Ellis; Oral Alpan; William R Lumry; Ralph Shapiro; Daniel Suez; J Fernando Mandujano; Richard L Wasserman Journal: Front Immunol Date: 2021-07-08 Impact factor: 7.561